These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23539537)

  • 1. Insights into pathological mechanisms of missense mutations in C-terminal domains of von Willebrand factor causing qualitative or quantitative von Willebrand disease.
    Yadegari H; Driesen J; Pavlova A; Biswas A; Ivaskevicius V; Klamroth R; Oldenburg J
    Haematologica; 2013 Aug; 98(8):1315-23. PubMed ID: 23539537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation.
    Wang JW; Groeneveld DJ; Cosemans G; Dirven RJ; Valentijn KM; Voorberg J; Reitsma PH; Eikenboom J
    Haematologica; 2012 Jun; 97(6):859-66. PubMed ID: 22207689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of cysteine 584 impairs the storage and release, but not the synthesis of von Willebrand factor.
    Daidone V; Barbon G; Pontara E; Cattini GM; Gallinaro L; Zampese E; Pizzo P; Casonato A
    Thromb Haemost; 2014 Dec; 112(6):1159-66. PubMed ID: 25230768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease.
    Tjernberg P; Vos HL; Spaargaren-van Riel CC; Luken BM; Voorberg J; Bertina RM; Eikenboom JC
    Thromb Haemost; 2006 Dec; 96(6):717-24. PubMed ID: 17139364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing multimer analysis of von Willebrand factor by single-molecule AFM imaging.
    Löf A; König G; Schneppenheim S; Schneppenheim R; Benoit M; Budde U; Müller JP; Brehm MA
    PLoS One; 2019; 14(1):e0210963. PubMed ID: 30645640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease.
    Schneppenheim R; Budde U; Obser T; Brassard J; Mainusch K; Ruggeri ZM; Schneppenheim S; Schwaab R; Oldenburg J
    Blood; 2001 Apr; 97(7):2059-66. PubMed ID: 11264172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand disease.
    Wang JW; Valentijn KM; de Boer HC; Dirven RJ; van Zonneveld AJ; Koster AJ; Voorberg J; Reitsma PH; Eikenboom J
    J Biol Chem; 2011 Jul; 286(27):24180-8. PubMed ID: 21596755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Storage and secretion of naturally occurring von Willebrand factor A domain variants.
    Groeneveld DJ; Wang JW; Mourik MJ; Dirven RJ; Valentijn KM; Voorberg J; Reitsma PH; Eikenboom J
    Br J Haematol; 2014 Nov; 167(4):529-40. PubMed ID: 25103891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced von Willebrand factor secretion is associated with loss of Weibel-Palade body formation.
    Castaman G; Giacomelli SH; Jacobi PM; Obser T; Budde U; Rodeghiero F; Schneppenheim R; Haberichter SL
    J Thromb Haemost; 2012 May; 10(5):951-8. PubMed ID: 22429825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients.
    Pagliari MT; Baronciani L; Cordiglieri C; Colpani P; Cozzi G; Siboni SM; Peyvandi F
    Haemophilia; 2022 Mar; 28(2):292-300. PubMed ID: 35064738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues.
    Tjernberg P; Vos HL; Castaman G; Bertina RM; Eikenboom JC
    J Thromb Haemost; 2004 Feb; 2(2):257-65. PubMed ID: 14995987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
    Eikenboom JC; Matsushita T; Reitsma PH; Tuley EA; Castaman G; Briët E; Sadler JE
    Blood; 1996 Oct; 88(7):2433-41. PubMed ID: 8839833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations C1157F and C1234W of von Willebrand factor cause intracellular retention with defective multimerization and secretion.
    Hommais A; Stépanian A; Fressinaud E; Mazurier C; Meyer D; Girma JP; Ribba AS
    J Thromb Haemost; 2006 Jan; 4(1):148-57. PubMed ID: 16409464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. von Willebrand factor propeptide missense variants affect anterograde transport to Golgi resulting in ER retention.
    Yadegari H; Biswas A; Ahmed S; Naz A; Oldenburg J
    Hum Mutat; 2021 Jun; 42(6):731-744. PubMed ID: 33942438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):111-8. PubMed ID: 19506357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease.
    Hommais A; Stépanian A; Fressinaud E; Mazurier C; Pouymayou K; Meyer D; Girma JP; Ribba AS
    Thromb Haemost; 2006 May; 95(5):776-81. PubMed ID: 16676067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.